Correction: Toll-like reReceptor 8 agonists improve NK-cell function primarily targeting CD56^brightCD16⁻ subset

Veneziani I, Alicata C, Pelosi A, et al. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56^brightCD16⁻ subset. J Immunother Cancer 2022;10:e003385. doi:10.1136/jitc-2021-003385

This article has been corrected since it was first published. An error with figure 2 and the supplemental material has been amended.